Last reviewed · How we verify
Epoetin Alfa-BioManguinhos
Epoetin Alfa-BioManguinhos is a Erythropoiesis-stimulating agent (ESA) Small molecule drug developed by Hospital de Clinicas de Porto Alegre. It is currently in Phase 3 development for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing major surgery.
Epoetin alfa stimulates erythropoiesis by binding to erythropoietin receptors on bone marrow progenitor cells, promoting red blood cell production.
Epoetin alfa stimulates erythropoiesis by binding to erythropoietin receptors on bone marrow progenitor cells, promoting red blood cell production. Used for Anemia associated with chronic kidney disease, Anemia in patients with cancer receiving chemotherapy, Anemia in patients undergoing major surgery.
At a glance
| Generic name | Epoetin Alfa-BioManguinhos |
|---|---|
| Sponsor | Hospital de Clinicas de Porto Alegre |
| Drug class | Erythropoiesis-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Epoetin alfa is a recombinant human erythropoietin that mimics the natural hormone responsible for regulating red blood cell production. It binds to erythropoietin receptors on erythroid progenitor cells in the bone marrow, triggering proliferation and differentiation into mature red blood cells. This mechanism is used to treat anemia by increasing hemoglobin and hematocrit levels.
Approved indications
- Anemia associated with chronic kidney disease
- Anemia in patients with cancer receiving chemotherapy
- Anemia in patients undergoing major surgery
Common side effects
- Hypertension
- Headache
- Thrombotic events (DVT, PE, stroke)
- Injection site reactions
- Fever
- Arthralgias
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Epoetin Alfa-BioManguinhos CI brief — competitive landscape report
- Epoetin Alfa-BioManguinhos updates RSS · CI watch RSS
- Hospital de Clinicas de Porto Alegre portfolio CI
Frequently asked questions about Epoetin Alfa-BioManguinhos
What is Epoetin Alfa-BioManguinhos?
How does Epoetin Alfa-BioManguinhos work?
What is Epoetin Alfa-BioManguinhos used for?
Who makes Epoetin Alfa-BioManguinhos?
What drug class is Epoetin Alfa-BioManguinhos in?
What development phase is Epoetin Alfa-BioManguinhos in?
What are the side effects of Epoetin Alfa-BioManguinhos?
What does Epoetin Alfa-BioManguinhos target?
Related
- Drug class: All Erythropoiesis-stimulating agent (ESA) drugs
- Target: All drugs targeting Erythropoietin receptor (EPOR)
- Manufacturer: Hospital de Clinicas de Porto Alegre — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Anemia associated with chronic kidney disease
- Indication: Drugs for Anemia in patients with cancer receiving chemotherapy
- Indication: Drugs for Anemia in patients undergoing major surgery
- Compare: Epoetin Alfa-BioManguinhos vs similar drugs
- Pricing: Epoetin Alfa-BioManguinhos cost, discount & access